SCHEMBL3341041

SCHEMBL3341041

Nc1cc(Cc2cccc(Cl)c2Cl)n[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 1/20 0.46
TAAR1 Q96RJ0 1/20 0.42
IDO1 P14902 2/20 0.41
AKR1B1 P15121 1/20 0.39
RECQL P46063 1/20 0.37
CHEK1 O14757 1/20 0.37
FLT3 P36888 1/20 0.37
PLK3 Q9H4B4 1/20 0.37
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
CCR2 P41597 1/20 0.36
CCR5 P51681 1/20 0.36
MPO P05164 2/20 0.36
GAA P10253 1/20 0.36
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
PTPN11 Q06124 1/20 0.34
AR P10275 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2928229 0.74 MPO (0.47) TAAR1IDO1AKR1B1MPOKDM4E
SCHEMBL13737504 0.73 HSP90AB1 (0.53) TAAR1MPOGAAALDH1A1POLB
SCHEMBL18148766 0.73 MPO (0.47) PNMTTAAR1IDO1MPO
SCHEMBL14720422 0.72 PNMT (0.46) PNMTTAAR1IDO1AKR1B1RECQL
SCHEMBL3302008 0.71 PNMT (0.68) PNMTTAAR1IDO1KDM4EALDH1A1
SCHEMBL14720127 0.70 PNMT (0.43) PNMTTAAR1IDO1AKR1B1RECQL
SCHEMBL14720231 0.70 PNMT (0.43) PNMTTAAR1IDO1AKR1B1RECQL
SCHEMBL956156 0.69 CDC7 (0.43) MPOALDH1A1ARHTR2CHTR2B
SCHEMBL14726285 0.69 IDO1 (0.51) IDO1CHEK1FLT3PLK3GAA
SCHEMBL14720145 0.68 PNMT (0.41) PNMTTAAR1IDO1AKR1B1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100152205-A1 CXCR2 INHIBITORS NOVARTIS AG 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152205-A1 CXCR2 INHIBITORS CXCR2, CXCR1, CXCR3 PNMT 4875/4885TAAR1 1583/4885IDO1 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.